查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572993

双相情感障碍治疗药物市场：按治疗药物、作用机制、给药途径、患者年龄组、最终用户和治疗期划分 - 2025-2030 年全球预测

Bipolar Disorder Therapeutics Market by Therapeutics, Mechanism Of Action, Drug Administration Route, Patient Age Group, End User, Treatment Duration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年双极性情感障碍治疗药物市值为60.1亿美元，预计2024年将达到63.7亿美元，复合年增长率为5.45%，预计到2030年将达到87.3亿美元。

双相情感障碍治疗药物市场的范围包括旨在稳定双相情感障碍相关情绪波动（例如躁狂、忧郁症和混合发作）的药物和治疗的开发、生产和分销。对创新性未满足需求的需求在于，由于双相情感障碍的复杂性，存在大量未满足的医疗需求，影响着全世界数百万人。应用包括情绪稳定剂、非典型抗精神病药物和抗忧郁症等药物，以及神经调节和心理治疗等新治疗方法。最终用途主要包括医疗机构、精神病诊所和研究机构，其驱动力是双相情感障碍盛行率不断上升、认识不断提高以及全球医疗基础设施的改善。

主要市场统计
基准年[2023] 60.1亿美元
预测年份 [2024] 63.7亿美元
预测年份 [2030] 87.3亿美元
复合年增长率（%） 5.45%

影响市场成长的关键因素包括双相情感障碍的盛行率不断上升、增强个人化医疗的药物基因组学的进步以及政府改善心理健康服务的倡议。然而，他们也面临严格的监管要求、高昂的研发成本、潜在的药物副作用以及与心理健康诊断和治疗相关的社会耻辱等挑战。儘管如此，透过增加研发投资、专注于精准医疗以及开发新型药物输送系统以改善治疗效果，该市场提供了巨大的成长机会。公司可以利用这些优势，与学术机构合作进行前沿研究，并扩大在医疗保健支出不断增加的新兴市场的影响力。

然而，市场参与企业必须应对一些限制，例如关键药物的专利到期导致学名药竞争以及全球市场监管一致性的需要。创新和研究可能会在探索联合治疗、先进诊断工具和支持治疗依从性和监测的数位心理健康干预措施方面得到发展。市场动态是动态的，强调技术进步和综合办法。利用人工智慧和机器学习在护理管理中进行预测分析仍然是业务成长和策略洞察力的一个有前途的领域。

市场动态：快速发展的双相情感障碍治疗市场的关键市场洞察

双极性情感障碍药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 新的数位健康技术能够有效管理双相情感障碍
    • 增加生物技术与药物研发投入，推动双极性情感疾患治疗创新
    • 扩大医疗基础设施和可近性，以改善双相情感障碍患者的治疗结果
    • 影响新双相情感障碍药物开发和核准的患者权益团体
  • 市场限制因素
    • 双相情感障碍新疗法的监管障碍和漫长的核准过程
    • 双相情感障碍研究和开发的资金和投资不足影响创新
  • 市场机会
    • 扩大远距精神病学服务，以提高双相情感障碍患者获得精神健康保健的机会
    • 将人工智慧融入双相情感障碍诊断和治疗计划
    • 心理健康意识提升和教育工作，以减少与双相情感障碍相关的耻辱
  • 市场挑战
    • 人群对双相情感障碍的认识和诊断有限阻碍了市场成长
    • 副作用的高发生率和患者对双极性情感障碍药物依从性差会影响治疗结果。

波特的五力：驾驭双极性情感障碍药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解双极性情感疾患药物市场的外在影响

外部宏观环境因素在塑造双极性情感障碍治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解双极性情感疾患治疗药物市场的竞争状况

双极性情感障碍治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

双极性情感障碍治疗药物市场供应商的 FPNV 定位矩阵绩效评估

FPNV 定位矩阵是评估双极性情感疾患治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为双相情感障碍治疗药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，双相情感障碍治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 新兴的数位健康技术可以更有效地管理双相情感障碍
      • 生物技术和药物研发投资的增加推动双相情感障碍治疗的创新
      • 扩大医疗基础设施和服务可改善双相情感障碍患者的治疗结果
      • 患者权益团体影响双相情感障碍新药的开发和核准
    • 抑制因素
      • 双相情感障碍新疗法的监管障碍和漫长的核准过程
      • 双相情感障碍研究和开发的资金和投资不足影响创新
    • 机会
      • 扩大远距精神病学服务，以提高双相情感障碍患者获得精神健康保健的机会
      • 将人工智慧融入双相情感障碍诊断和治疗计划
      • 努力提高心理健康意识和教育，以减少与双相情感障碍相关的耻辱
    • 任务
      • 公众对双相情感障碍的认识和诊断有限阻碍了市场成长
      • 双极性情感障碍药物副作用发生率高且患者依从性差会影响治疗结果
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 双极性情感疾患治疗药物市场治疗

  • 抗惊厥药
    • Carbamazepine
    • 拉莫三嗪
  • 抗忧郁症
    • Fluoxetine
    • 帕罗西汀
    • 舍曲林
    • 文拉法辛
  • 抗精神病药
    • Aripiprazole
    • Olanzapine
    • Quetiapine
    • Risperidone
  • 情绪稳定剂
    • 拉莫三嗪
    • 碳酸锂
    • 丙戊酸

第七章双极性情感疾患治疗药物市场（依作用机转）

  • GABA促效剂
  • 麸胺酸促效剂
  • 离子通道阻断剂
  • 单胺类药物

第八章依药品管理途径分類的双极性情感疾患治疗药物市场

  • 肌肉注射
  • 静脉
  • 口服

第九章按患者年龄分類的双相情感障碍治疗药物市场

  • 青春期
  • 成人用
  • 老年病
  • 小儿科

第 10 章 双极性情感障碍治疗药物市场：依最终使用者分类

  • 家庭护理设置
  • 医院
    • 住院病人
    • 门诊病人
  • 专科诊所
    • 情绪障碍诊所
    • 精神科诊所

第十一章依治疗时期分類的双极性情感疾患治疗药物市场

  • 急性
  • 维护

第十二章北美和南美双相情感障碍治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太双极性情感障碍治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第14章欧洲、中东和非洲双极性情感障碍治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0280

The Bipolar Disorder Therapeutics Market was valued at USD 6.01 billion in 2023, expected to reach USD 6.37 billion in 2024, and is projected to grow at a CAGR of 5.45%, to USD 8.73 billion by 2030.

The scope of the Bipolar Disorder Therapeutics market encompasses the development, production, and distribution of medications and treatments aimed at stabilizing mood swings associated with bipolar disorder, including manic, depressive, and mixed episodes. The necessity for innovative bipolar disorder therapeutics lies in the considerable unmet medical needs due to the disorder's complex nature, affecting millions worldwide. Applications cover pharmaceuticals like mood stabilizers, atypical antipsychotics, and antidepressants, alongside emerging therapies such as neuromodulation and psychotherapy. The end-use scope primarily involves healthcare institutions, psychiatric clinics, and research institutes, driven by an increasing prevalence of bipolar disorder, rising awareness, and improving healthcare infrastructure globally.

KEY MARKET STATISTICS
Base Year [2023] USD 6.01 billion
Estimated Year [2024] USD 6.37 billion
Forecast Year [2030] USD 8.73 billion
CAGR (%) 5.45%

Key factors influencing market growth include the growing incidence of bipolar disorder, advancements in pharmacogenomics enhancing personalized medicine, and government initiatives to improve mental health services. Conversely, the market faces challenges like stringent regulatory requirements, high R&D costs, potential side effects of drugs, and social stigma associated with mental health diagnosis and treatment. Nonetheless, the market presents significant growth opportunities through increased investment in R&D, focusing on precision medicine, and developing novel drug delivery systems to improve therapeutic outcomes. Companies can capitalize on these by collaborating with academic institutions for advanced research and expanding their presence in emerging markets with rising healthcare expenditure.

However, market players need to address limitations such as patent expirations of key drugs leading to generic competition, and the need for regulatory alignment across global markets. Innovation and research can thrive in areas exploring combination therapies, advanced diagnostic tools, and digital mental health interventions that support therapy adherence and monitoring. The nature of the bipolar disorder therapeutics market is dynamic, with an emphasis on technological advancements and comprehensive patient-centered approaches. Harnessing artificial intelligence and machine learning for predictive analytics in treatment management remains a promising area for business growth and strategic insight.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bipolar Disorder Therapeutics Market

The Bipolar Disorder Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Emerging digital health technologies enabling more efficient management of bipolar disorder
    • Growing investment in biotechnology and pharmaceutical R&D driving innovation in bipolar disorder treatments
    • Expansion of healthcare infrastructure and accessibility improving patient outcomes for bipolar disorder
    • Patient advocacy groups influencing the development and approval of new bipolar disorder medications
  • Market Restraints
    • Regulatory hurdles and lengthy approval processes for new bipolar disorder therapeutic drugs
    • Insufficient funding and investment in bipolar disorder research and development affecting innovation
  • Market Opportunities
    • Expansion of telepsychiatry services to enhance access to mental health care for bipolar disorder patients
    • Integration of artificial intelligence in diagnostics and treatment planning for bipolar disorder
    • Initiatives to increase mental health awareness and education to reduce stigma associated with bipolar disorder
  • Market Challenges
    • Limited awareness and diagnosis of bipolar disorder among the population hinders market growth
    • High prevalence of side effects and low patient adherence to bipolar disorder medications affect treatment outcomes

Porter's Five Forces: A Strategic Tool for Navigating the Bipolar Disorder Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bipolar Disorder Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bipolar Disorder Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bipolar Disorder Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bipolar Disorder Therapeutics Market

A detailed market share analysis in the Bipolar Disorder Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bipolar Disorder Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bipolar Disorder Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bipolar Disorder Therapeutics Market

A strategic analysis of the Bipolar Disorder Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bipolar Disorder Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Bipolar Disorder Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics, market is studied across Anticonvulsants, Antidepressant Drugs, Antipsychotic Drugs, and Mood Stabilizers. The Anticonvulsants is further studied across Carbamazepine and Lamotrigine. The Antidepressant Drugs is further studied across Fluoxetine, Paroxetine, Sertraline, and Venlafaxine. The Antipsychotic Drugs is further studied across Aripiprazole, Olanzapine, Quetiapine, and Risperidone. The Mood Stabilizers is further studied across Lamotrigine, Lithium Carbonate, and Valproate Acid.
  • Based on Mechanism Of Action, market is studied across GABAergic Agents, Glutamatergic Agents, Ion Channel Blockers, and Monoaminergic Drugs.
  • Based on Drug Administration Route, market is studied across Intramuscular, Intravenous, and Oral.
  • Based on Patient Age Group, market is studied across Adolescent, Adult, Geriatric, and Pediatric.
  • Based on End User, market is studied across Homecare Settings, Hospitals, and Specialty Clinics. The Hospitals is further studied across Inpatient and Outpatient. The Specialty Clinics is further studied across Mood Disorder Clinics and Psychiatric Clinics.
  • Based on Treatment Duration, market is studied across Acute and Maintenance.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Emerging digital health technologies enabling more efficient management of bipolar disorder
      • 5.1.1.2. Growing investment in biotechnology and pharmaceutical R&D driving innovation in bipolar disorder treatments
      • 5.1.1.3. Expansion of healthcare infrastructure and accessibility improving patient outcomes for bipolar disorder
      • 5.1.1.4. Patient advocacy groups influencing the development and approval of new bipolar disorder medications
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory hurdles and lengthy approval processes for new bipolar disorder therapeutic drugs
      • 5.1.2.2. Insufficient funding and investment in bipolar disorder research and development affecting innovation
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of telepsychiatry services to enhance access to mental health care for bipolar disorder patients
      • 5.1.3.2. Integration of artificial intelligence in diagnostics and treatment planning for bipolar disorder
      • 5.1.3.3. Initiatives to increase mental health awareness and education to reduce stigma associated with bipolar disorder
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and diagnosis of bipolar disorder among the population hinders market growth
      • 5.1.4.2. High prevalence of side effects and low patient adherence to bipolar disorder medications affect treatment outcomes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bipolar Disorder Therapeutics Market, by Therapeutics

  • 6.1. Introduction
  • 6.2. Anticonvulsants
    • 6.2.1. Carbamazepine
    • 6.2.2. Lamotrigine
  • 6.3. Antidepressant Drugs
    • 6.3.1. Fluoxetine
    • 6.3.2. Paroxetine
    • 6.3.3. Sertraline
    • 6.3.4. Venlafaxine
  • 6.4. Antipsychotic Drugs
    • 6.4.1. Aripiprazole
    • 6.4.2. Olanzapine
    • 6.4.3. Quetiapine
    • 6.4.4. Risperidone
  • 6.5. Mood Stabilizers
    • 6.5.1. Lamotrigine
    • 6.5.2. Lithium Carbonate
    • 6.5.3. Valproate Acid

7. Bipolar Disorder Therapeutics Market, by Mechanism Of Action

  • 7.1. Introduction
  • 7.2. GABAergic Agents
  • 7.3. Glutamatergic Agents
  • 7.4. Ion Channel Blockers
  • 7.5. Monoaminergic Drugs

8. Bipolar Disorder Therapeutics Market, by Drug Administration Route

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intravenous
  • 8.4. Oral

9. Bipolar Disorder Therapeutics Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adolescent
  • 9.3. Adult
  • 9.4. Geriatric
  • 9.5. Pediatric

10. Bipolar Disorder Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Homecare Settings
  • 10.3. Hospitals
    • 10.3.1. Inpatient
    • 10.3.2. Outpatient
  • 10.4. Specialty Clinics
    • 10.4.1. Mood Disorder Clinics
    • 10.4.2. Psychiatric Clinics

11. Bipolar Disorder Therapeutics Market, by Treatment Duration

  • 11.1. Introduction
  • 11.2. Acute
  • 11.3. Maintenance

12. Americas Bipolar Disorder Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Bipolar Disorder Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Bipolar Disorder Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkermes plc
  • 3. Allergan plc
  • 4. Amgen Inc.
  • 5. AstraZeneca
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. GlaxoSmithKline plc
  • 9. Johnson & Johnson
  • 10. Lundbeck A/S
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Otsuka Pharmaceutical Co., Ltd.
  • 15. Pfizer Inc.
  • 16. Sanofi
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Supernus Pharmaceuticals, Inc.
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. BIPOLAR DISORDER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BIPOLAR DISORDER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BIPOLAR DISORDER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIPOLAR DISORDER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIPOLAR DISORDER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GABAERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GLUTAMATERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ION CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOAMINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD DISORDER CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZ